Brought to you by 
Biovail buys two of Wyeth's marketed drugs
24 Jul 2003
Executive Summary
Biovail Corp. (large, integrated Canadian biotech that specializes in delivery formulations and sells both its own and in-licensed products) will pay $130mm for the US rights to two of Wyeth's marketed oral drugs.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail buys two of Wyeth's marketed drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice